Patents Assigned to Oncodesign S.A.
-
Patent number: 10676486Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.Type: GrantFiled: September 17, 2015Date of Patent: June 9, 2020Assignee: ONCODESIGN S.A.Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
-
Patent number: 10377772Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.Type: GrantFiled: September 17, 2015Date of Patent: August 13, 2019Assignee: Oncodesign S.A.Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
-
Publication number: 20190127390Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.Type: ApplicationFiled: September 17, 2015Publication date: May 2, 2019Applicant: ONCODESIGN S.A.Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
-
Publication number: 20170240565Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.Type: ApplicationFiled: September 17, 2015Publication date: August 24, 2017Applicants: Oncodesign S.A., Ipsen Pharma S.A.S.Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
-
Patent number: 9586975Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.Type: GrantFiled: March 14, 2014Date of Patent: March 7, 2017Assignee: ONCODESIGN S.A.Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack, Pascal Andre Rene Benderitter
-
Patent number: 9370519Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.Type: GrantFiled: June 19, 2015Date of Patent: June 21, 2016Assignee: Oncodesign S.A.Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack
-
Publication number: 20160024113Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of SIK kinase, more in particular SIK1, SIK2 and/or SIK3 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of SIK-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Applicant: ONCODESIGN S.A.Inventors: Petra Marcella, Francoise BLOM, Jan Marie, Cyriel, Jozef HOFLACK, Pascal Andre, Rene BENDERITTER
-
Publication number: 20160024114Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.Type: ApplicationFiled: March 14, 2014Publication date: January 28, 2016Applicant: ONCODESIGN S.A.Inventors: Petra Marcella, Francoise Blom, Jan Marie Cyriel Jozef Hoflack, Pascal Andre, Rene Benderitter
-
Patent number: 9096609Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.Type: GrantFiled: September 28, 2012Date of Patent: August 4, 2015Assignees: Ipsen Pharma S.A.S., Oncodesign S.A.Inventors: Jan Hoflack, Petra Blom
-
Patent number: 9090630Abstract: The present invention relates to macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of FLT3 (FMS-Related Tyrosine kinase 3). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.Type: GrantFiled: September 28, 2012Date of Patent: July 28, 2015Assignee: Oncodesign S.A.Inventors: Petra Marcella Francoise Blom, Jan Marie Cyriel Jozef Hoflack